Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK 1 inhibitor GSK 2982772 in healthy volunteers

Abstract GSK 2982772 is a highly selective inhibitor of receptor‐interacting protein kinase 1 ( RIPK 1) being developed to treat chronic inflammatory diseases. This first‐in‐human study evaluated safety, tolerability, pharmacokinetics ( PK ), and exploratory pharmacodynamics ( PD ) of GSK 2982772 administered orally to healthy male volunteers. This was a Phase I, randomized, placebo‐controlled, double‐blind study. In Part A, subjects received single ascending doses of GSK 2982772 (0.1‐120 mg) or placebo in a crossover design during each of 4 treatment periods. In Part B, subjects received repeat doses of GSK 2982772 (20 mg once daily [ QD ] to up to 120 mg twice daily [ BID ]) or placebo for 14 days. Part C was an open‐label relative bioavailability study comparing 20‐mg tablets vs capsules. Safety, tolerability, pharmacokinetics ( PK ), RIPK 1 target engagement ( TE ), and pharmacodynamics ( PD ) were assessed. The most common adverse events ( AE s) were contact dermatitis and headache. Most AE s were mild in intensity, and there were no deaths or serious AE s. The PK of GSK 2982772 was approximately linear over the dose range studied (up to 120 mg BID ). There was no evidence of drug accumulation upon repeat dosing. Greater than 90% RIPK 1 TE was achieved over a 24‐hour period for the 60‐mg and 120‐mg BID dosing regimens. Single and repeat doses of GSK 2982772 were safe and well tolerated. PK profiles showed dose linearity. The high levels of RIPK 1 TE support progression into Phase II clinical trials for further clinical development.